Acitretin in combination with UVB or PUVA - 07/09/11
Abstract |
Combination therapy of psoriasis with acitretin and phototherapy (psoralen–ultraviolet A [PUVA] or ultraviolet B [UVB]) offers multiple advantages over use of either modality alone. As monotherapy, acitretin in doses of 50 mg/day is moderately effective, but is associated with numerous side effects. Single modality treatment with UVB or PUVA involves multiple visits over a period of months and is also associated with dose-limiting side effects. When used in combination, lower doses of both modalities can be used more effectively, helping to reduce side effects. In addition, clearing occurs much more quickly, reducing treatment time and number of phototherapy visits. Moreover, patients whose psoriasis does not clear with monotherapy will often achieve significant clearing with the combination of acitretin and phototherapy. (J Am Acad Dermatol 1999;41:S22-4.)
Le texte complet de cet article est disponible en PDF.Plan
 | From the Department of Dermatology, The Mount Sinai School of Medicine, New York. |
| This manuscript is based on a presentation given at the 5th European Congress on Psoriasis/7th International Psoriasis Symposium in Milan, Italy on September 2, 1998, with support from Roche Laboratories, Inc., Nutley, NJ. |
 | Reprint requests: Mark Lebwohl, MD, One Gustave L. Levy Place, New York, NY 10029. |
| 0190-9622/99/$8.00 + 0 16/0/100484 |
Vol 41 - N° 3S
P. S22-S24 - septembre 1999 Retour au numéro
Article précédent
- Acitretin combination therapy
- Henry H. Roenigk
- Systemic sequential therapy of psoriasis: A new paradigm for improved therapeutic results
- John Koo
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?